Form 8-K - Current report:
SEC Accession No. 0001999371-25-020361
Filing Date
2025-12-16
Accepted
2025-12-16 07:05:37
Documents
14
Period of Report
2025-12-16
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tonix-8k_121625.htm   iXBRL 8-K 29097
2 PRESS RELEASE ex99-01.htm EX-99.01 24660
3 GRAPHIC image_001.gif GRAPHIC 2173
  Complete submission text file 0001999371-25-020361.txt   231251

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnxp-20251216.xsd EX-101.SCH 2990
5 XBRL LABEL FILE tnxp-20251216_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE tnxp-20251216_pre.xml EX-101.PRE 22342
16 EXTRACTED XBRL INSTANCE DOCUMENT tonix-8k_121625_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251573339
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)